Eftilagimod alfa is an experimental medication being studied for its potential to help the immune system fight cancer. It works by activating certain immune cells, which may enhance the body’s ability to attack cancer cells. In this trial, it is being tested in combination with other treatments to see if it can improve outcomes for patients with advanced lung cancer.

Pembrolizumab is a medication that helps the immune system recognize and attack cancer cells. It is known as a PD-1 antagonist, which means it blocks a specific protein on immune cells that can prevent them from attacking cancer. By blocking this protein, pembrolizumab can help the immune system better target and destroy cancer cells.

Chemotherapy refers to a group of medications used to kill or slow the growth of cancer cells. In this trial, chemotherapy is used alongside other treatments to see if the combination can be more effective in treating advanced lung cancer. Chemotherapy works by targeting rapidly dividing cells, which include cancer cells, to reduce the size of tumors and slow the progression of the disease.

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer that begins in the cells lining the lungs and is characterized by its ability to spread to other parts of the body. It is termed “non-small cell” because the cancer cells are larger than those found in small cell lung cancer. In its advanced or metastatic stage, the cancer has spread beyond the lungs to other organs. The progression of the disease can vary, but it often involves the growth of tumors in the lungs and potentially in other areas such as the bones, brain, or liver. Symptoms may include persistent cough, chest pain, and difficulty breathing. The disease is typically diagnosed through imaging tests and biopsy, and its progression is monitored through regular medical evaluations.